Adrian Gottschalk, Foghorn Therapeutics CEO (Flagship Pioneering via YouTube)
June 5, 2023 10:50 AM EDT
R&D

FDA lifts clin­i­cal hold on Foghorn’s study for blood and bone mar­row can­cer treat­ment

Tyler Patchen

News Reporter

Foghorn Ther­a­peu­tics, a gene-fo­cused biotech, has been giv­en the all-clear to pro­ceed with a tri­al as­sess­ing its ther­a­py aimed at treat­ing can­cers found in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times